Expression of pAkt affects p53 codon 72 polymorphism-based prediction of response to radiotherapy in nasopharyngeal carcinoma by Xiaoxue Xie et al.
Xie et al. Radiation Oncology 2013, 8:117
http://www.ro-journal.com/content/8/1/117RESEARCH Open AccessExpression of pAkt affects p53 codon 72
polymorphism-based prediction of response to
radiotherapy in nasopharyngeal carcinoma
Xiaoxue Xie1†, Hui Wang1†, Hekun Jin1, Shuyu Ouyang1, Jumei Zhou1, Jun Hu3, Xuping Xi1, Junming Luo1,
Yingying Zhang2 and Bingqiang Hu1*Abstract
Background: Codon 72 (Arg/Pro), the most frequently studied single nucleotide polymorphism (SNP) of p53 to
date, is associated with the ability of the gene to induce cell apoptosis. The PI3K/Akt pathway plays an essential
role in the transcriptional activation function of p53, and is an important factor in radiotherapy resistance. The
present study was designed to evaluate the prediction of response to radiotherapy based on p53 codon 72 SNP
and pAkt expression in biopsy specimens of locoregional nasopharyngeal carcinoma (NPC) before treatment.
Materials and methods: In total, 75 consecutive patients with locoregional NPC were enrolled. The p53 codon 72
SNP was identified from retrospectively collected paraffin-embedded biopsy specimens using Sanger sequencing.
Expression patterns of p53, p21, 14-3-3σ, and pAkt proteins were investigated using immunohistochemical analyses.
The effects of genetic polymorphisms and protein expression on progression-free survival (PFS) were evaluated
using the Cox proportional hazards model, Kaplan–Meier method, and log-rank test.
Results: The p53 codon 72 Pro/Pro carriers showed lower risk of disease progression (local recurrence and distant
metastases) (HR: 0.300; 95% CI: 0.092–0.983; p=0.047). However, this association between the p53 codon 72
polymorphism and PFS was not significant in the pAkt-positive subgroup. No association was observed between
protein expression of p53, p21 or 14-3-3σ and p53 codon72 polymorphisms. Notably, positive expression of p53
protein appeared to be correlated with poorer PFS among patients diagnosed as local regional lymph node
metastasis (N+) before treatment (p=0.032).
Conclusions: The p53 codon 72 Pro/Pro genotype may be an effective independent prognostic marker for better
outcome in patients with locoregional NPC. Based on the current findings, we hypothesize that pAkt weakens the
predictive value of p53 codon 72 SNP in NPC. A combination of positive p53 protein expression and local regional
lymph node metastasis may additionally be predictive of high risk of disease progression.
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Nasopharyngeal carcinoma (NPC) is an epithelial malig-
nancy with an annual incidence of 15 to 50 cases per
100,000 individuals in Southern China [1]. The progno-
sis of patients with NPC in the early stages is generally
favorable, although the incidence of relapse remains high* Correspondence: bingqianghu@hotmail.com
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reproduction in any medium, provided the orfor locoregionally advanced NPC [2,3]. Radiotherapy
remains the primary mode of treatment for locoregional
NPC. In the present study, we focused on evaluating the
predictive value of the p53 pathway in outcomes of pa-
tients with locoregional NPC in response to radiother-
apy. The p53 gene is thought to be central in mediating
response to commonly used cancer treatments, such as
radiotherapy. Codon 72 (Arg/Pro) is the most frequently
studied SNP in the p53 gene to date. The amino acid
encoded by codon 72 resides in a poly proline region
located between the transactivation and DNA binding. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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critical for p53 function, particularly its ability to induce
apoptosis. Numerous studies have provided evidence
that the two different isoforms encoded by p53 codon 72
SNP are not functionally equivalent [4-8]. In a number of
cancer types, including lung and breast, patients with the
72Pro-p53 allele appear to be more susceptible to tumor
development [9-12]. However, there is no consensus
regarding the correlation between treatment susceptibility
and p53 polymorphism at codon 72 in cancers. For
example, Vannini et al. [13] reported a significantly
shorter time of disease progression and overall survival in
metastatic breast cancer patients homozygous for Arg,
compared to those with heterozygous Arg/Pro tumors.
Conversely, Kim et al. [14] reported that Arg/Pro and Pro/
Pro genotypes of TP53 codon 72 are significantly correlated
with a lower response rate to combination chemotherapy,
compared to the Arg/Arg genotype in advanced gastric
cancer. Results from a meta-analysis [15] showed that
homozygote Arg/Arg genotype is more significantly associ-
ated with decreased risk of NPC, compared with the Pro/
Pro genotype. However, the precise relationship between
the TP53 codon 72 polymorphism and clinical outcomes of
NPC remains to be established.
The phosphatidylinositol-3-kinase (PI3K)/protein kinase
B (Akt) pathway plays an essential role in the tran-
scriptional activation function of p53 and consequent
modulation of cell fate. Notably, EGFR-independent
activation of the PI3K/Akt pathway, a common occurrence,
is an important factor in radiotherapy resistance [16]. Akt is
a downstream effector of PI3kinase in NPC possibly associ-
ated with aggressive tumor behavior and poor survival in
patients with nasopharyngeal carcinoma [17]. The existing
paradigm about the nature of interactions between the PI3-
kinase and p53 pathways is antagonistic, whereby pAkt
inhibits p53 function in a Mdm2-dependent manner
[18-20]. Under conditions where the apoptotic activity
of p53 prevails, it is conceivable that the destruction of
pAkt plays a role in accelerating the apoptotic process.
The relationship between p53 activation and cell fate
regulation is extremely complex [21]. Boehme et al. [22]
proposed a signaling cascade involving activation of
DNA-PK and Akt/PKB for the regulation of p53 in
response to ionizing radiation. Suvasini et al. [23] also
reported an essential function of PI3-kinase and its
downstream effectors, Akt/PKB-mTOR, in activating
p53-mediated transcription during DNA damage. In the
cell membrane, Akt is activated through phosphoryl-
ation at serine and threonine residues, and modulates
the expression of several genes involved in suppression
of apoptosis and cell cycle progression. The mechanism
by which the DNA damage-induced PI3K/Akt pathway
alters p53 phosphorylation at critical residues is not
clear at present. However, reduced Lys382 acetylation inLY294002-treated cells may be explained by the finding that
p300, which acetylates p53, is activated by Akt-mediated
phosphorylation [24]. Thus, the classical identification
of the ‘pro-survival’ PI3K/Akt and ‘pro-apoptotic’ p53
pathways adds another layer of complexity to the out-
come of NPC.
The present study was designed to evaluate prediction
of response to radiotherapy on the basis of p53 codon 72
SNP and p53 pathway protein expression in locoregional
nasopharyngeal carcinoma (NPC) biopsy specimens before
treatment. To our knowledge, this is the first study to focus
on assessing the combined prognostic effects of p53 codon
72 SNP and pAkt expression.
Materials and methods
Patient selection
Between January 2008 and October 2009, 75 consecutive
patients with locoregional NPC at the Department of
Radiation and Oncology of the Hunan provincial tumor
hospital were enrolled retrospectively in this study.
Patients with proven biopsy and previously untreated
NPC with American Joint Committee on Cancer (AJCC)/
International Union Against Cancer (UICC) stages II, III
and IV (A-B) were eligible for study. Other criteria included
ages greater than 18 years, Han Chinese ethnicity, and an
Eastern Cooperative Oncology Group performance status
of 0 or 1. The exclusion criteria included presence of distant
metastasis and other concomitant malignant disease. The
study was approved by the Clinical Research Ethics
Committee of the Hunan Province Cancer Center, and writ-
ten informed consent was obtained from all patients. Patient
characteristics are summarized in Table 1. In total, 57 male
and 18 female patients (male-to-female ratio of 3.2:1)
with a median age of 45 years (range, 22–72 years)
were enrolled. All patients were diagnosed as World
Health Organization (WHO) Grade 2–3 NPC. Among
our patient population, 16 had stage II, 44 had stage
III, and 15 had stage IV (A-B) disease.
Pretreatment evaluation
All patients were evaluated using complete physical
examination, fiberoptic nasopharyngoscopy, MRI of the
head and neck, chest X-ray, abdominal imaging with
ultrasound, and bone scan.
Treatment
Megavoltage photons (6 MV) were used to treat primary
tumor and neck lymph nodes. Radiotherapy was adminis-
tered five times a week at a dose of 2 Gy/d. The accumu-
lated radiation dose to the primary tumor was 68 to 72 Gy,
60 to 62 Gy to the involved areas of the neck, and 50 Gy
to uninvolved areas. Concurrent chemoradiotherapy,
specifically, DDP (100 mg/m 2) on days 1, 22, and 43 during
radiotherapy, was administered to 39 patients.
Table 1 Patient demographics and treatment
characteristics
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The primary end point for the study was progression-
free survival (PFS), defined as the time from the day of
enrollment to the date of first documentation of relapse
categorized as locoregional (primary site or regional nodes)
failure, distant metastases or last follow-up visit.
Sample preparation, DNA extraction and quantification of
DNA yield
From each sample, eight 10 μm tissue sections were
deparaffinized using xylene and ethanol. Specimens were
digested with proteinase K for 24 h at 55C. Subsequently,
the enzyme was inactivated by boiling the samples for
10 min prior to mixing with absolute ethyl alcohol. After
purification with ion-exchange columns, genomic DNA
was stored at -20C before use.
DNA amplification and genotyping procedures
Nested PCR method was used to amplify specific frag-
ments. The PCR reaction was performed in three steps: 5
min at 95C, followed by 35 cycles of 30 s at 95C, 30 s at
55C, and 40 s at 72C, and finally, 10 min at 72C. Prior
to Sanger sequencing, amplified products were identi-
fied by electrophoresis using BigDye Terminator v3.1chemistry (Life Technologies, Carlsbad, CA) on an Applied
Biosystems 3130XL Genetic Analyzer. All PCR reactions
and sequencing analyses were performed twice to confirm
the results.
Immunohistochemical studies
Immunohistochemistry (IHC) was performed on sections
of 75 NPC tissues using standard techniques. Tissue
sections were deparaffinized in xylene, rehydrated in a
graded ethanol series, and treated with an antigen retrieval
solution (10 mmol/L sodium citrate buffer, pH 6.0). Next,
sections were incubated with mouse anti-human p53 anti-
body (1:200 dilution) overnight at 4C and 1:1,000 diluted
biotinylated secondary antibody, followed by avidin-biotin
peroxidase complex (DAKO, Carpinteria, CA), according
to the manufacturer’s instructions. Finally, tissue sections
were treated with 3’, 3’-diaminobenzidine (Sigma) until the
development of brown color, and counterstained with
Harris modified hematoxylin. In negative controls, primary
antibodies were omitted. The procedure for staining pAkt,
p21, and 14-3-3σ was similar to that for p53 IHC staining,
except that the anti-p53 antibody was replaced with
anti-pAkt (Thr308)(Santa Cruz Biotechnology, Inc.),
anti-p21(ZSGB-BIO), and anti-14-3-3σ(Abcam) antibodies,
respectively. Sections were blindly evaluated by two in-
vestigators in an effort to provide a consensus on staining
patterns. A semiquantitative scoring criterion for immu-
nohistochemistry was used in which both staining inten-
sity and positive areas were recorded according to the
method of Hara et al. [25]. At least 10 high-power fields
were selected randomly, and >1,000 cells counted for each
section. Staining intensity was graded on the following
scale: 0: no staining, 1+: mild staining, 2+: moderate stain-
ing, and 3+: intense staining. The area of staining was
scored as follows: 0: no staining in any microscopic field,
1+: <30% of tissue stained positive, 2+: between 30% and
60% stained positive, and 3+: >60% stained positive. The
minimum score, when summed (extension+ intensity),
was 0, and the maximum score was 6. For 14-3-3σ and
pAkt, a combined staining score (extension+ intensity)
of ≤ 3 was considered negative (low staining), and that
between 4 and 6 considered positive. For p53 and p21, a
combined staining score (extension+ intensity) of ≤ 4
was considered negative (low staining), and that between
5 and 6 considered positive. Representative results of
p53, p21, pAkt, and 14-3-3σ immunohistochemistry are
shown in Figure 1.
Follow-up studies
The follow-up analysis was completed on October 31,
2012, with a median follow-up of 25 (range, 5–46) months.
After completion of treatment, patients were followed up at
least every three months during the first years and every six
months thereafter until disease progression (recurrence or
Figure 1 Representative results of p53, p21, pAkt, and 14-3-3σ imunohistochemistry in NPC tissues. Brown nuclear staining of tumor cells
for p53 shown in A (× 100) and B (× 400), and for p21 in C (× 100) and D (× 400), and brown cytoplasm staining of tumor cells for pAkt shown
in E (× 100) and F (× 400) and for 14-3-3σ in G (× 100) and H (× 400).
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based on fiberoptic endoscopy and biopsy and/or MRI of
the nasopharynx and the skull base showing progressive
bone erosion and/or soft tissue swelling. Regional recur-
rences were diagnosed by clinical examination of the neck
and, in doubtful cases, fine needle aspiration or MRI of
the neck. Distant metastases were diagnosed on the basis
of clinical symptoms, physical examination and imaging
methods, including chest radiography, abdominal ultra-
sound, whole body bone scan, CT scan, and MRI. During
follow-up, 22 (29.3%) patients had locoregional relapse and
21 (28.0%) had distant metastasis. No patients died during
follow-up. The 3-year PFS rate was 42.7% (32/75).Statistical analysis
The correlation between IHC results and p53 codon
72 genotypes was evaluated using Pearson χ2 test. The
Hardy–Weinberg equilibrium was tested using a
goodness-of-fit χ2 test with one degree of freedom. The
Kaplan–Meier method was adopted to estimate survival
curves, and the log-rank test used to compare patient
survival times between subgroups. Multivariate analyses
using Cox regression were employed to assess the im-
portance of clinical variables, with adjustment for age,
gender, T classification, N classification, and concurrent
chemotherapy. Analyses were carried out using the stat-
istical software package SPSS 17.0 (SPSS). All statistical
Figure 2 Typical raw data obtained using Sanger sequencing
instruments for p53 codon 72 (G>C) polymorphisms. Note: The
area between the yellow lines indicates the resulting genotypes; p53
codon72 G is equivalent to Arg and C is equivalent to Pro.
Table 3 Association between p53 codon 72 genotypes and
p53/p21/14-3-3σ protein expression (Chi-square analysis)
p53 codon 72 genotypes
Protein expression Arg/Arg Arg/Pro Pro/Pro p
p53 Positive 20 16 6 0.423
Negative 12 13 6
p21 Positive 8 5 3 0.748
Negative 23 25 9
14-3-3σ Positive 18 17 3 0.100
Negative 13 13 9
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statistically significant.
Results
The p53 codon72 polymorphism was clearly distinguished
via Sanger sequencing. Typical sequencing peak diagrams
are depicted in Figure 2. The frequency of the Arg allele
was 0.23, fulfilling the Hardy-Weinberg distribution.
We observed no significant association between the p53
codon72 SNP and clinical variables (Table 2). ExpressionTable 2 Correlation of p53 codon 72 genotypes with clinical v
Arg/Arg Arg/Pro
T1-2 T3-4 T1-2 T3
17(40.48%) 16(48.48%) 19(45.24%) 11(3
N0 N+ N0
8(50%) 25(42.37%) 5(31.25%) 25(4
Stage II Stage III-IV Stage II Stag
7(43.75%) 26(44.7%) 7(43.75%) 23(3patterns of p53, p21, and 14-3-3σ were not affected by p53
codon72 polymorphisms (Table 3).
For clinical variables, only T classification was associated
significantly with the time to disease progression (Figure 3)
(p=0.005). However, both T (HR: 2.683; 95% CI: 1.430–
5.032; p=0.002) and N (HR: 1.778; 95% CI: 1.196–2.644;
p=0.004) classifications were significantly correlated with 3-
year PFS rates after adjustment for age (<45 and ≥45 years),
gender (male and female), and concurrent chemotherapy
(yes or no) (Table 4). Hazard ratios (HR) for disease
progression (distant metastases and local recurrence) were
significantly lower for Pro/Pro p53 codon 72 carriers after
adjustment (HR: 0.300; 95% CI: 0.092–0.983; p=0.047)
(Table 4). However, no overall association was evident
between p53, p21 or 14-3-3σ protein expression and
PFS (Table 4).
As shown in Figure 4A, positive p53 protein expression
was correlated with poorer PFS in a subgroup of patients
diagnosed with lymph node metastasis (N+) before
initial treatment (p=0.032). Kaplan-Meier PFS curves
were obtained according to p53 codon 72 SNP and
p53 expression, respectively (Figure 4). Patients carrying
the Pro/Pro p53 codon 72 SNP displayed a longer time to
disease progression than those with other polymorphic
variants (p=0.043, Figure 4B). This result was significant
in the pAkt-negative (p=0.034, Figure 4C), but not the
pAkt-positive subgroup (p=0.388, Figure 4D).
Results of analysis of the combined effects of the p53
codon72 polymorphism and pAkt protein expression on
risk of disease progression (local recurrence and distant
metastases) are shown in Table 5. According to log-rankariables (Chi-square analysis)
Pro/Pro p
-4cp T1-2 T3-4
3.33%) 6(14.29%) 6(18.18%) 0.810
N+ N0 N+
2.37%) 3(18.75%) 9(15.25%) 0.842
e III-IV Stage II Stage III-IV
8.98%) 2(12.5%) 10(16.95%) 0.842
Figure 3 Kaplan-Meier PFS curves according to clinic stages.
Kaplan-Meier PFS curves according to T classification (A), N
classification (B) and overall stage (C).
Table 4 Multivariate analysis of progress-free survival
(PFS) using the Cox proportional hazards model
Variables Subgroups HR 95%CI p
T classification T3-4 vs. T1-2 2.683 1.430-5.032 0.002
N classification N+ vs. N0 1.778 1.196-2.644 0.004
p53 codon
72 genotype
C/C vs. G/C+G/G 0.300 0.092-0.983 0.047
p53 protein Positive vs. Negative 1.714 0.893-3.291 0.105
pAkt protein Positive vs. Negative 1.025 0.542-1.938 0.939
p21 protein Positive vs. Negative 0.745 0.338-1.641 0.465
14-3-3σ protein Positive vs. Negative 1.440 0.764-2.711 0.259
Abbreviations: HR, hazard ratio; CI, confidence interval.
Note: p53 codon72 G is equivalent to Arg and C is equivalent to Pro.
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genotype displayed significantly longer time to disease
progression, compared to those with other genotypes, in
the pAkt-negative subgroup (p=0.034). However, this
result was not significant upon assessment with the
Cox proportional hazards model (p=0.191). Moreover,
no significant association between the p53 codon72
polymorphism and PFS was observed in the pAkt-
positive subgroup.
Discussion
In the present study, patients carrying p53 codon 72
Pro/Pro displayed better PFS than those with other
polymorphisms. Multivariate analysis of the three-year
PFS rate with both Cox proportional hazards model
and log-rank analysis of time to disease progression
suggested that the p53 codon72 polymorphism is
an independent predictor of response to radiotherapy
in nasopharyngeal carcinoma.
Pro72 and Arg72 variants are reported to differ in
terms of functional activity. Specifically, the Pro72 variant
possesses enhanced ability to transactivate p21 and induce
growth arrest [4,6,26,27], while the Arg72 variant demon-
strates superior mitochondrial localization in tumor cell
lines [5]. Interestingly, Dumont and co-workers showed
that the Arg72 variant is more efficient than the Pro72
variant in inducing apoptosis. One possible mechanism
underlying this greater efficiency is enhanced localization
of the Arg72 variant to mitochondria [5]. In contrast, our
results suggest that the p53 codon72 Pro/Pro genotype is
associated with improved PFS in locoregional NPC pa-
tients. A recent study showed binding of the p53 homolog,
p73, to specific tumor-derived mutant forms of p53, which
is influenced by the codon 72 polymorphism. It was
proposed that several common mutants of mtp53-
codon72-Arg bind with greater affinity to p73, thereby
inhibiting its ability to induce apoptosis [28-31]. How-
ever, the p53 gene is rarely mutated in nasopharyngeal
carcinoma [32]. Additionally, the Arg72 variant has been
Figure 4 Kaplan-Meier PFS curves according to P53. Kaplan-Meier PFS curves according to protein expression of p53 (positive vs. negative)
among patients diagnosed as local regional lymph node metastasis (A); Kaplan-Meier PFS curves according to dominant model of p53 codon 72
SNPs (C/C vs. G/C+G/G) (B); Kaplan-Meier PFS curves according to dominant model of p53 codon 72 SNPs (C/C vs. G/C+G/G) in the pAkt-
negative (C) and pAkt-positive subgroups (D). Note: p53 codon72 G is equivalent to Arg and C is equivalent to Pro.
Xie et al. Radiation Oncology 2013, 8:117 Page 7 of 10
http://www.ro-journal.com/content/8/1/117shown to be more susceptible to degradation by the human
papillomavirus (HPV) 18 E6 protein [33]. Approximately
15–20% of head-and-neck squamous cell carcinomas
(HNSCC) may be linked to HPV infection [34-36]. Ac-
cordingly, the effect of HPV on response to radiother-
apy of Arg72 variant carriers in NPC requires further
study. Other mechanisms should also be considered.
For example, Vannini et al. [13] provided a molecular
explanation for association of the Arg allele with tumor
aggressiveness and treatment resistance in advanced
breast cancer. The group demonstrated that lower cell
death is induced under hypoxia upon transfection ofTable 5 Log-rank and proportional hazard analysis (Cox meth








G/G +G/C Positive 24.66±2.38
C/C Positive 29.86±6.72
G/G +G/C Negative 25.79±2.48
C/C Negative 40.60±2.04
Note: p53 codon 72 G is equivalent to Arg and C is equivalent to Pro.the Arg allele, compared to Pro allele in vitro, which was
explained by the finding that the Arg allele upregulates
BCRP-I, a hypoxia response gene, that increases treatment
resistance. While the precise molecular mechanisms under-
lying these differences in apoptosis merit further study,
these observations suggest that determination of the patient
genotype at p53 codon 72 may aid in identifying patient
populations with poorer response to radiotherapy.
The prognostic value of p53 protein expression in NPC
has been investigated, but the results obtained to date are
controversial. The groups of Faccioli [37], Genc [38], Shi
[39], and Tsai [40] reported that p53 overexpression is notod) of progression-free survival (PFS) in relation to p53
lysis Cox-regression
p HR 95% CI p
— 1 reference —
0.388 0.626 0.187-2.096 0.447
— 1 reference —
0.034 0.034 0.00-5.394 0.191
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vival. However, Ma et al. [41] suggested that overexpression
of p53 protein is related to poorer disease-free survival and
a trend towards shorter time to progression, but not overall
survival. In contrast, Masuda et al. [42] reported that p53
overexpression is associated with lower overall survival.
Moreover, Wang and co-workers [43] demonstrated a sig-
nificant association of p53 protein overexpression with
locoregional recurrence of patients with NPC, but no im-
pact on the 5-year survival rate. The present study also fo-
cused on p53 protein as a potential predictive marker of
response to radiotherapy for locoregional NPC. Notably,
expression of p53 protein was not affected by p53 codon
72 polymorphisms (Table 3). Moreover, no significant asso-
ciation was evident between p53 protein expression and
PFS (Table 4). Nevertheless, patients expressing p53
showed poorer PFS among those diagnosed with
locoregionally lymph node metastasis (N+) before treat-
ment (p=0.032) (Figure 4C). Our data indicate that a com-
bination of positive p53 protein expression and local
regional lymph node metastasis can be effectively used to
predict poorer outcomes.
P21/waf1 has been described as a wild-type p53-inducible
protein involved in inhibition of cell cycle progression
through binding to cyclin/cyclin-dependent-kinase (CDK)
complex. Earlier studies have provided evidence that after
DNA damage, p53 enhances p21/waf1 transcription, which,
in turn, inhibits the formation of cyclin-CDK complexes,
blocking progression along the cell cycle in the G1-S
transition stage [44]. 14-3-3σ, a downstream target of
p53, is upregulated in response to DNA damage, and
acts as a negative regulator of cell cycle G2-M phase
checkpoint. Moreover, 14-3-3σ interacts with p53 and
positively potentiates its activity [45]. Yang et al. [46]
found that overexpression of 14-3-3σ in NPC cells inhibits
cell growth, sensitizes cells to apoptosis, counteracts Akt
oncogenic signaling, and reduces tumorigenicity in nude
mice. The function of 14-3-3σ as a potential tumor sup-
pressor gene in NPC was similarly confirmed by Yi et al.
[47]. Accordingly, we attempted to determine whether the
predictive effect of p53 codon 72 polymorphism is corre-
lated with p21 and 14-3-3σ expression. In our experiments,
p21 and 14-3-3σ protein levels were not affected by p53
codon 72 polymorphisms. Based on this finding, we
propose that the predictive value of p53 codon72 in re-
sponse to radiotherapy for NPC is not associated with the
regulation of downstream proteins, p21 and 14-3-3σ.
The PI3K/Akt pathway plays an essential role in the tran-
scriptional activation functions of p53, thereby modulating
cell fate decisions. Retrospective studies by Schuurbiers et
al. [48] showed that pAkt expression is an independent
prognostic indicator of clinical outcomes of lung cancer.
Yip et al. [17] reported that Akt is activated in 42.2% and
35.9% NPC cases, based on pAkt (Thr308) and pAkt(Ser473) immunoreactivity, respectively. The group further
demonstrated that pAkt promotes cell proliferation and
survival and is critical in NPC pathogenesis. In the present
study, positive expression of pAkt (Thr308) protein was
detected in 48.53% (33/72) of the subjects. No significant
association between pAkt and PFS was observed. However,
pAkt protein expression appeared to affect the relation-
ship between p53 codon72 polymorphisms and out-
comes in NPC patients. Subjects carrying the p53
codon72 Pro/Pro genotype showed longer time to dis-
ease progression, compared to patients with other geno-
types (p=0.043, Figure 4A). This result was significant
among subgroups with negative pAkt protein expression
(p=0.034, Figure 4B), while no significant association be-
tween p53 codon 72 polymorphisms and PFS was found in
the pAkt-positive subgroup. According to Ogawara et al.,
both Akt expression and serum treatment increase MDM2
ubiquitination of p53 [20]. It has been reported that p53
phosphorylated at Ser-20 escapes degradation by Mdm2,
leading to stabilization of the protein [49]. Ozeki et al. con-
firmed that Mdm2-mediated degradation of 72Arg-p53 is
diminished, compared to 72Pro-p53, which is at least partly
attributable to higher levels of Ser-20 phosphorylation in
p53-72R [50]. One possibility is that 72Pro-p53 is more eas-
ily down regulated via activation of the PI3K/Akt pathway,
compared to 72Arg-p53. Therefore, the PI3K-Akt pathway
may contribute to cell fate determination via selective
inhibition of 72Pro-p53 accumulation. As a result, the p53
codon72 Pro/Pro carriers show no superiority in terms of
response to radiotherapy in the pAkt-positive subgroup.
Our data collectively suggest that the p53 codon72 Pro/
Pro genotype of the p53 gene in locoregional NPC is a
useful prognostic marker for identifying the patient
populations that respond poorly to radiotherapy, particu-
larly in those negative for pAkt expression.
Conclusions
We have shown that the p53 codon72 Pro/Pro genotype
presents an independent predictor of better outcome in
locoregional NPC patients. Positive expression of pAkt
appears to act as a suppressor of this predictive function
of the p53 codon72 Pro/Pro genotype. We observed no
involvement of p21 and 14-3-3σ expression in the mech-
anism underlying the predictive value of p53 codon72 in
response to radiotherapy in NPC. In addition, our results
indicate that a combination of positive p53 protein ex-
pression and local regional lymph node metastasis may
effectively act as a positive predictor of high risk of dis-
ease progression.
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